Turist Financial Remains a Buy on Nuvation Bio (NUVB)

Company Overview - Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology patients, particularly targeting rare and difficult-to-treat cancers with its lead asset, IBTROZI (taletrectinib) [4] Analyst Ratings and Price Targets - Gregory Renza from Truist Financial reiterated a Buy rating on Nuvation Bio and raised the price target from $11 to $13, while Soumit Roy from JonesTrading assigned a Buy rating with a $12 price target [1][2] - The increase in price target is based on the company's Q4 2025 pre-report and a meeting with the company's management, highlighting a robust opportunity for the Ibtrozi franchise [2] Market Opportunities - Analysts noted that the Ibtrozi franchise presents a stronger-than-expected upside, positioning the drug as the ROS1 agent of choice despite seasonal headwinds [2] - Truist also expressed optimism regarding the company's mIDH1 glioma opportunity, awaiting clarity on registrational timelines, with key study readouts potentially arriving as early as 2026 [3]